Positive results from RSV antiviral human challenge trial conducted by hVIVO Larger human challenge trial provides valuable insights for candidate development

Official launch of full suite of hLAB standalone services Health & Safety Executive (HSE) clearance received for containment level 3 (CL-3) laboratory

The exceptional operational delivery across the Group in H1 24 resulted in record revenues of £35.6m, 30.6% higher than H1 2023.

hVIVO plc (AIM & Euronext: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that

hVIVO plc (AIM & Euronext: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its

Octopus Investments recently increased its stake in hVIVO (LON: HVO), which operates the world’s largest commercial human challenge trial unit. The investment group now holds 7.61% of hVIVO’s equity, raising

We have an extensive history, that dates back to the UK Common Cold Unit in Salisbury which ran human challenge studies from 1946 until 1989.

Broker Cavendish reaffirmed its 42p price target for hVIVO PLC (AIM: HVO) stock after a capital markets day (CMD) at the company’s new state-of-the-art quarantine facility in Canary Wharf.